The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. This is the Type 1 Diabetes report. It details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for people with type 1 diabetes. The 2019-20 audit covers the period 01 January 2019 to 31 March 2020. This is the first NDA report dedicated to people with type 1 diabetes. A new diagnosis validation process, which considers medication as well as recorded diagnosis, has been introduced to try to ensure that only people with true type 1 diabetes are included (see appendix). Results are to be taken in the context of low data submission from specialist services, possibly hampered due to COVID-19.

The National Diabetes Register was introduced in 2016 by the amendment of Act No. 372/2011 Coll. , on health services and conditions of their provision (Act on Health Services), by Act No. 147/2016 Coll. with effect from 1 July 2016.

It is a new type of register that uses as much as possible already existing data in the healthcare sector, namely the data of the National Register of Reimbursed Health Services (NRHZS), i.e. the administrative data of health insurance companies supplemented by data from laboratories that already exist in their information systems and data collection from nursing staff physicians involved in a referral network of providers or in planned observational studies.

Risk and prognostic factors of the disease, data related to the disease and its treatment, personal and family history of the patient related to the disease, including classification of the type and state of diabetes and laboratory values, provision of dispensary care are processed in the register; data needed to identify the provider diagnosing, treating and providing dispensary care.

The basic statistical unit of the record in the register is the record of diabetes.

The register provides an overview of a population-relevant disease from the point of view of epidemiology, treatment and control of diabetes at a hitherto inaccessible detailed level with minimal effort, as it is mostly the use of already existing data.

Mandatory duties and irreplaceable functions of the register:

• Monitoring the epidemiology of diabetes and its treatment as a socially extremely serious disease affecting a significant part of the population
• Monitoring the quality and outcomes of diabetes care
• Data reporting for EUROSTAT, WHO, OECD databases

This is an overview of the treatment and demographics of 227,435 adults with type 1 diabetes. From 2019 to 2022 glucose control in people with type 1 diabetes in England and Wales improved while blood pressure control deteriorated. Use of diabetes technology (wearable glucose monitoring devices in England and insulin pumps in England and Wales) was associated with lower glucose levels. Diabetes technology was used less by those in the most deprived groups and in ethnic minorities. 30% of people with type 1 diabetes did not attend specialist care in 2021-22 and were less likely to receive annual checks or achieve treatment targets as recommended by the National Institute for Health and Care Excellence (NICE). There are 3 recommendations for commissioners of care.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The NDA measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards, in England and Wales. The NDA collects and analyses data for use by a range of stakeholders to drive changes and improvements in the quality of services and health outcomes for people with diabetes. This report details the findings and recommendations relating to diabetes care process completion, treatment target achievement and structured education for the 2018-19 audit. The audit collected data during May and June 2019, for the period 01 January 2018 to 31 March 2019. This report follows the NDA short report publication in December 2019, which provided the top level findings for the 2018-19 audit, along with local level data made available to services in a timely manner that can help drive improvements in the quality of diabetes care locally. A new method of collecting structured education attendance data was trialled for 2018-19. In addition to extracting education data from GP practice systems, structured education providers could submit data directly via the Clinical Audit Platform (CAP). Around 20 providers submitted, however only a small proportion of records were submitted with the required data. This exercise has shown the potential value of this additional collection and improvements to the process are being developed to improve future collections. Included within this publication is the National Diabetes Insulin Pump Audit interactive reporting and supporting information. It provides information on people with Type 1 diabetes on an insulin pump at National, LHB, and Specialist Diabetes Service level for the 2018-19 audit period. Note: An error was identified in the original release of the National Diabetes Insulin Pump Audit 2018-19, Interactive Report for Specialist Services in England. The number of people with Type 1 diabetes in the 'HbA1c values' section was overstated and showed the total number of people with any type of diabetes seen at the service. This has been corrected and replaced with a new version of the report on 23 December 2020.

The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. This NICE guidance is based on evidence that regular systematic review of people with diabetes and achievement of glucose, blood pressure and cardiovascular risk standards maintains health and reduces long term complications.

Audit collects Information about general diabetes care. Data submitted by health care services, relevant to service they provide i.e. Secondary Care Bodies = Type 1, GP practices = Type 2. Includes demographics and diabetes relevant biometric information.

Financial overview and grant giving statistics of National Diabetes Research Foundation

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded by NHS England. The NDA is managed by NHS Digital in partnership with Diabetes UK. The National Diabetes Audit (NDA) provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against NICE Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations. Identify gaps or shortfalls that are priorities for improvement. Identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for 2020-21 (1st January 2020 – 31st March 2021). Data were collected during May and June 2021. The national report, scheduled for 2022, will contain commentary on the audit findings and recommendations. We will communicate to users when the publication date for this report has been finalised. Note: An issue was identified with the Wales data release whereby structured education offered data was underreported. This has now been corrected in the version of the file available on this webpage.

Analysis of risk factors for pre-diabetes and undiagnosed type 2 diabetes among adults living in private households, using the Health Survey for England.

This statistic depicts the raw national prevalence of diabetes in the Middle East in 2013, by selected countries. In that year, the raw national prevalence of diabetes Oman was approximately ***** percent.

The National Diabetes Insulin Pump Audit is part of the National Diabetes Audit (NDA).

The National Diabetes Insulin Pump Audit collects information on the number and characteristics of people with Type 1 diabetes using an insulin pump, the reasons for going on an insulin pump and the outcomes achieved since starting on the pump.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Insulin Pump Audit data for 2016-17 is available at England and Wales, Local Health Board (LHB) and Specialist Diabetes Service level for:

• Participation
• Patient demographics
• Prevalence
• Care process completion
• Treatment targets
• Diabetes characteristics

Using and interpreting the data

Data from the National Diabetes Insulin Pump Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Local Health Boards and Specialist Diabetes Services are identified by organisation code.

What does the data cover?

The audit looks at the following areas:

• Reason for starting on an insulin pump
• Care processes
• Treatment targets
• Structured Education

What period does the data cover?

This data covers the top level findings from the 2016-17 National Diabetes Insulin Pump Audit for the period 1 January 2016 to 31 March 2017. This National Report was published on 14 June 2018.

The information available from this webpage comes from the National Diabetes Audit - Diabetes Prevention Programme report.

The NHS Diabetes Prevention Programme (NHS DPP) is a joint commitment from NHS England, Public Health England and Diabetes UK to deliver, at scale, evidence based behavioural interventions that can prevent or delay the onset of Type 2 diabetes in adults who have been identified as having non-diabetic hyperglycaemia.

This report uses data collected alongside the National Diabetes Audit (NDA) for the period January 2017 to March 2018 inclusive.

This report is for England only. Unlike the NDA, it does not include information on Wales.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

What information is being made available?

National Diabetes Audit - Diabetes Prevention Programme data for 2017-18 is available at England, Clinical Commissioning Group (CCG) and GP practice-level for:

• Patient list size
• Patient demographics
• Diabetes characteristics
• Diabetes Prevention Programme take-up

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Audit - Diabetes Prevention Programme should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Audit - Diabetes Prevention Programme will be made available in CSV format. Hospitals are identified by name and their national code.

What does the data cover?

The audit looks at the following areas:

• Registrations and prevalence
• Offers of DPP
• Demographics

What period does the data cover?

This report covers data collected alongside the National Diabetes Audit (NDA) for the period January 2017 to March 2018 inclusive. The audit report was published on 11 July 2019.

This dataset is a compilation of easy tips to prevent type 2 diabetes. They were compiled from several documents produced by the National Diabetes Education Program (NDEP). NDEP is a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations.

In 2021, the global prevalence rate of diabetes among adults figured at **** percent - about *********** people aged between 20 and 79 years. In China, the prevalence rate amounted to **** percent, indicating a gradual increase over the recent decade. The world's most populous country had the highest number of diabetics in the world. Who is suffering from diabetes? Diabetes although a common enough ailment, is far more notorious than one would choose to believe. Affecting a rather large portion of the global population, the disease does not discriminate between the young or old. The main categories of diabetes include type one, type two, and gestational diabetes. Type two diabetes accounts for the vast majority - around ** percent of diabetes worldwide, affecting young and older adults. Type one, on the other hand, is primarily found in children owing to genetics, a family history of diabetes or other external factors. How is diabetes affecting the Red Dragon? The economic loss from diabetes is significant. It is now among the top ten leading causes of death worldwide and was estimated to cause about *********** deaths in China in 2021. Between 2015 and 2019, China spent a double more on diabetes-related healthcare. Besides, the prevalence of prediabetes is also alarming. On par with an increasing prevalence rate of diabetes among adults, the average spending per patient for treatment has also been climbing, though still far lower than that in other strong economies. This could mean a huge market potential for diabetes medication and devices in China, especially when the government has planned to raise the public awareness of diabetes, along with national health spending.

Making clinical audit data transparent

In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. In September 2016 the National Diabetes Inpatient Audit was conducted in hospitals across England and Wales, collecting data on characteristics of the hospital including staffing structures, patient clinical data and patient experience information.

What information is being made available?

 Audit participation and data completeness for the key fields

 Measures about the process of care given to patients

 Information about care outcomes and treatment.

These data do not list individual patient information nor do they contain any patient identifiable data.

Using and interpreting the data

Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care.

Accessing the data

The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code.

What does the data cover?

The audit looks at the following areas:

• Did diabetes management minimise the risk of avoidable complications?

• Did harm result from the inpatient stay?

• Was patient experience of the inpatient stay favourable?

• Has the quality of care and patient feedback changed?

What period does the data cover?

This data covers patients surveyed on a date between 26 and 30 September 2016. The audit report was published on 08 March 2017.

The National Diabetes Audit (NDA) is part of the National Clinical Audit and Patient Outcomes Programme (NCAPOP) which is commissioned by the Healthcare Quality Improvement Partnership (HQIP) and funded and managed by NHS England, in partnership with Diabetes UK. The NDA provides a comprehensive view of diabetes care in England and Wales. It measures the effectiveness of diabetes healthcare against National Institute for Health and Care Excellence (NICE) Clinical Guidelines and NICE Quality Standards. The NDA supports improvement in the quality of diabetes care by enabling participating NHS services and organisations to: Assess local practice against NICE guidelines. Compare their care, and care outcomes, with similar services and organisations, identify gaps or shortfalls that are priorities for improvement, identify and share best practice and provide a comprehensive national picture of diabetes care and outcomes in England and Wales. This data release includes the care process and treatment target measurements for the full 2023-24 audit period (1 January 2023 – 31 March 2024); presented for England primary care, Wales primary care and specialist services (hospital-based care), each with its own separate data file. Data from primary care in England was collected throughout the audit period. Data for specialist services in England is submitted throughout the year with the January 2023 to March 2024 cut of this data being taken in May 2024. Data from Wales was received in June 2024.

The information available from this webpage comes from the National Diabetes Inpatient Audit. The National Diabetes Inpatient Audit is a snapshot audit of diabetes inpatient care. During September 2019, hospitals across England collected data on the characteristics of the hospital, including participation, staffing levels and care improvement initiatives. Wales did not participate in NaDIA 2019. Making clinical audit data transparent In his transparency and open data letter to Cabinet Ministers on 7 July 2011, the Prime Minister made a commitment to make clinical audit data available from the national audits within the National Clinical Audit and Patient Outcomes Programme. What information is being made available? National Diabetes Inpatient Audit data for 2019 is available at hospital site level for: * Audit participation and data completeness for the key fields * Measures about the process of care given to patients * Information about care outcomes and treatment. These data do not list individual patient information nor do they contain any patient identifiable data. Using and interpreting the data Data from the National Diabetes Inpatient Audit should not be looked at in isolation when assessing standards of care. Accessing the data The data are being made available on the data.gov website. Each year a data file from the National Diabetes Inpatient Audit will be made available in CSV format. Hospitals are identified by name and their national code. What period does the data cover? This report covers hospital characteristics during September 2019. The audit report was published on 13 November 2020. Historic data is available for previous audit years (2010-2013, 2015-2017) where survey questions were comparable.

This dataset contains number and percentage of diabetes patients in the US during 2013 grouped by ZIP code. The prevalence and incidence of diabetes have increased in the United States in recent decades, no studies have systematically examined long-term, national trends in the prevalence and incidence of diagnosed diabetes.